An announcement from Johnson & Johnson yesterday said that the company is projecting filings with regulatory authorities for approval of two new drugs for the treatment of advanced prostate cancer between 2017 and 2021. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: apalutamide, ARN-509, niraparib | 2 Comments »
A report posted on line in European Urology has provided us with important clinical data related to the potential of this investigational drug in the treatment of advanced prostate cancer. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: apalutamide, ARN-509, outcomes, trials | Leave a comment »
Back in June 2013, Johnson & Johnson acquired Aragon Pharmaceuticals and the investigational agent ARN-509 — a potential “precursor” to abiraterone acetate (see below). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: ARN-509, outcome, Phase III, trial | 7 Comments »
According to a media release issued by the company earlier today, Johnson & Johnson has made a definitive agreement to acquire Aragon Pharmaceuticals, Inc., including all rights to Aragon’s androgen receptor antagonist program. … READ MORE …
Filed under: Uncategorized | Tagged: ARN-509 | 2 Comments »
A whole host of new data on drugs like sipuleucel-T, enzalutamide, abiraterone, and others was available in the poster sessions at the Genitourinary Cancers Ssympisum in Orlando today. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: abiraterone, aflibercept, ARN-509, cabazitaxel, cediranib, dasatinib, enzalutamide, radium-223, sipuleucel-T | 6 Comments »
We have previously discussed the early development of ARN-509 as a novel, second-generation, antiandrogenic agent for the potential treatment of men with advanced prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: advanced, ARN-509, casteration-resistant | 2 Comments »
There has clearly been a good deal of interest in the data on ARN-509 reported at the recent meeting of the European Society of Medical Oncology (ESMO) … at least from the investment community. … READ MORE …
Filed under: Drugs in development | Tagged: ARN-509, data, trial | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 